11/01/2019 05:05:00

BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA

NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today announced that Ralph Kern MD, MHSc, Chief Operating Officer and Chief Medical Officer, will provide a clinical update for the ongoing phase 3 pivotal trial of NurOwn® in ALS patients at the 9th Annual California ALS Research Summit in Irvine, California.

The California ALS Research Summit is an annual meeting of researchers, investigators, clinicians, biotech companies, government representatives, partner organizations, and advocates in ALS and related fields in California.

9

th

Annual California ALS Research Summit Details:

Date:                      Friday, January 11, 2019

Time:                      2:00-2:30pm Pacific Time

Location:                Arnold and Mabel Beckman Center of the National Academy of Sciences

Agenda:                 https://sites.google.com/a/alsagoldenwest.org/california-als-research-summit/schedule

About NurOwn

®

NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm is currently conducting a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis (MS) and plans to start enrollment in early 2019.

About BrainStorm Cell Therapeutics Inc.               

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm is currently enrolling a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit BrainStorm's website at www.brainstorm-cell.com.

Safe-Harbor Statements        

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at https://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Media:

Joseph Petroziello

BrainStorm Cell Therapeutics

Phone: +1.215.485.6797

Email:  JP@brainstorm-cell.com

Investors:

Marcy Beth Nanus

Solebury Trout

Phone: +1.646.378.2927

Email: MNanus@troutgroup.com

download.jpg

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Jan
I:SP500
  Hejsa    Jeg har igen vedlagt vores langsigtede konjunkturmodel med de ledende indikatorer i USA, ..
39
17 Jan
PNDORA
Jeg vil bare henlede opmærksomheden paa Lars Christensens artikel omkring "Short Selling", direkte h..
37
18 Jan
PNDORA
En stor tak til alle jer, der har givet mig en like (ialt 32). Det er dejligt at vide, at vi er mang..
20
19 Jan
I:NDX
Har lige opdaget at man kan trykke på en knap og sende en like. Men hvad skal man bruge det til? Alt..
18
19 Jan
 
Jeg deltog i går i en spørgeseance med CEO for Euronav Paddy Rodgers. Euronav er et pure play på råo..
18
16 Jan
VWS
Din indsigt i verdensfirmaet Vestas er forbløffende!
14
22 Jan
DANSKE
Det kan jo aldrig falde tilbage på en bank eller dens aktionærer at der er en flok institionelle inv..
13
22 Jan
GOMX
Update fra SASg i morges: 29 customers signed with expected annualised revenues of $10 - $12M from 1..
13
18 Jan
ROV
Ja, og de to ovenstående kommentarer er i den grad med til at forringe og forsimple debatniveauet he..
13
17 Jan
PNDORA
Udfordringen er, at der hele tiden sker en bekræftigelse af at Pandoras fald er faldende uden nogle ..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
LoRa Alliance Passes 100 LoRaWAN™ Network Operator Milestone with Coverage in 100 Countries
2
General Cannabis Continues Expansion with Latest Office Opening in Los Angeles and Renovation of 15,000 Square Foot Denver Headquarters
3
Distilled Identity and Emerge Announce Technology Partnership to Solve Global Identity Crisis for Refugees
4
Bloomington-Normal Association of Realtors® Successfully Goes Live with Midwest Real Estate Data
5
Update on Parys Mountain Optimisation Study

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 January 2019 01:58:09
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190121.1 - EUROWEB5 - 2019-01-23 02:58:09 - 2019-01-23 01:58:09 - 1000 - Website: OKAY